| Samantha Wilks, | |
|
151 Summit Ave, Summit, NJ 07901-2813 | |
| (908) 598-0228 | |
| Not Available |
| Full Name | Samantha Wilks |
|---|---|
| Gender | Female |
| Speciality | Speech-language Pathologist |
| Location | 151 Summit Ave, Summit, New Jersey |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1285009191 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 235Z00000X | Speech-language Pathologist | 41YS00786700 (New Jersey) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Samantha Wilks, 151 Summit Ave, Summit, NJ 07901-2813 Ph: () - | Samantha Wilks, 151 Summit Ave, Summit, NJ 07901-2813 Ph: (908) 598-0228 |
News Archive
Pernix Therapeutics Holdings, Inc., a specialty pharmaceutical company primarily focused on the pediatric market, today announced the acquisition of 100% of the outstanding membership interest in Macoven Pharmaceuticals, L.L.C. for approximately $2.2 million (which includes inventory of approximately $1.2 million), its entry into a $10 million credit facility with Regions Bank and the repurchase of 2,000,000 shares of its common stock from one of its employees in a privately negotiated transaction.
Amerigroup Corporation today announced that net income for the second quarter of 2011 was $44.3 million, or $0.83 per diluted share, versus net income of $67.2 million, or $1.31 per diluted share, for the second quarter of 2010 and compared to $70.5 million, or $1.37 per diluted share, for the first quarter of 2011.
Low back pain in the elderly is the result of poor "proprioception," or the body's ability to perceive its own position in space, caused by a deterioration of sensory receptors in their muscles called proprioceptors.
Edison Pharmaceuticals today announced the initiation of a phase 2 study entitled "A Phase 2 Safety and Efficacy Study of EPI-743 (Vincerinone™) in Children with Pearson Syndrome." The Investigative New Drug application (IND) was approved by the Food and Drug Administration, Office of Hematology and Oncology Products.
In monitoring and prediction of children's growth, the spurt in puberty is often considered too variable to be predictable. However, new findings and methods enable a better picture of how children and adolescents grow, especially during puberty.
› Verified 4 days ago
Samantha Ann Notte, MS CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 151 Summit Ave, Summit, NJ 07901 Phone: 908-598-0228 Fax: 908-598-0175 | |
Marla Faith Wolfe, M.S., CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 57 Union Pl, Summit, NJ 07901 Phone: 908-273-5537 | |
Stephanie Marie Whitney, MS Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 151 Summit Ave, Summit, NJ 07901 Phone: 908-598-0228 | |
Heidi Miller, MS CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 151 Summit Ave, Lower Level, Summit, NJ 07901 Phone: 908-598-0228 Fax: 908-598-0175 | |
Kelly Garcia, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 151 Summit Ave, Summit, NJ 07901 Phone: 732-491-1123 | |
Margot Elizabeth Tobias, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 46 Valley View Ave, Summit, NJ 07901 Phone: 908-370-4941 | |
Olivia Arlene Thorson, M.S., CF-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 151 Summit Ave, Summit, NJ 07901 Phone: 908-598-0228 |